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OsteoporosisPurpose: The aim of this studywas to estimate the rate of gastrointestinal (GI) events, and association between GI
events and compliance with osteoporosis therapy among osteoporotic women.
Methods: A retrospective cohort study using a large administrative claims database in the United States from
2001 through 2010 was conducted. We studied women ≥55 years old who were continuously enrolled in a
health plan for at least 2 years, a baseline year before and a follow-up year after the date of the ﬁrst prescription
of oral bisphosphonate as the ﬁrst oral osteoporosis treatment. Compliance with osteoporosis therapy was mea-
sured using the medication possession ratio (MPR), with compliance deﬁned as MPR ≥0.8. Multivariate logistic
regressionwas used to assess the association between occurrence of GI events and compliancewith osteoporosis
therapy after controlling for demographic and clinical characteristics.
Results: A sample consisting of 75,593 women taking at least one oral bisphosphonate with mean (SD) age of 64
(8) years was identiﬁed. A total of 21,142 (28%) patients experienced at least one GI event during the follow-up
period. Only 31,306 (41%) patients were compliant with osteoporosis therapy. Patients who experienced GI
events after initiation of oral bisphosphonateswere 29% less likely to adhere to osteoporosis therapy as compared
to patients who did not experience GI events (odds ratio [95% CI], 0.71 [0.69–0.74]; P b .001).
Conclusions: Less than half of the patients were compliant with osteoporosis therapy within one year after initi-
ating oral bisphosphonates, and the likelihood of compliancewas signiﬁcantly lower by 29% amongwomenwith
GI events.
© 2015 Merck & Co., Inc. Published by Elsevier Inc.1. Introduction
Osteoporosis is a systemic skeletal disease characterized by low
bone mass and micro-architectural deterioration of bone tissue, with a
consequent increase in bone fragility and susceptibility to fracture. Pri-
marily occurring in postmenopausal women as they age and to a lesser
degree in older men, osteoporosis is typically a disease without symp-
toms until a fracture occurs (Siris et al., 2001), with resultant pain, de-
creased quality of life, acute and sometimes chronic disability, and, in
the case of hip fracture, an increase in mortality (Dempster, 2011;
Adachi et al., 2010). The substantial personal and societal burden of
osteoporotic fracture is accompanied by a large and rising economic
burden. In the United States (US) alone, the direct medical costs of
osteoporotic fracture were estimated at $16.9 billion in 2005 and are
projected to rise to $25.3 billion by 2025 (Burge et al., 2007).r Inc.An estimated 30% of women and 19% of men 50 years and older in
the US are at elevated risk of osteoporotic fracture and are considered
eligible for pharmacologic treatment (Dawson-Hughes et al., 2012).
There are several available therapies with proven efﬁcacy for reducing
fracture risk in patients with osteoporosis. Among them, the oral
bisphosphonates, including alendronate, risedronate, and ibandronate,
are the most commonly used agents. However, suboptimal compliance
with osteoporosis therapies is a common and well-recognized problem
in the real world of clinical practice, outside of clinical trials (Cramer
et al., 2007; Kothawala et al., 2007; Li et al., 2012); and poor compliance
results in increased risk of fracture, higher medical costs, increases in
hospitalizations, and wasted medications (Halpern et al., 2011;
Sampalis et al., 2011; Ross et al., 2011; Hadji et al., 2012). Improving
compliance with osteoporosis therapies is thus an important goal for
both policy makers and clinicians.
In randomized controlled trials, oral bisphosphonates are generally
well-tolerated, with upper gastrointestinal (GI) events and discontinu-
ation rates similar to those of placebo (Bauer et al., 2000; Liberman,
2006). The occurrence of GI events among patients using oral
bisphosphonates is common in real world clinical practice (Hamilton
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often difﬁcult to determine whether GI events are related to the use of
oral bisphosphonates, other medication (e.g., NSAIDs), or are due to an-
other new or preexisting GI condition. However, the understanding of
the association between occurrence of GI events and compliance with
osteoporosis therapy among patients using oral bisphosphonates,
particularly among a US managed care population, is limited.
The objective of this study was to estimate the rate of GI events
and the association between GI events and compliance with




A retrospective cohort study was conducted using the i3 Invision
Datamart, a large administrative claims database covering 45 million
patients from geographically diverse areas in the US. Longitudinal de-
identiﬁed patient information in the database includes demographic
characteristics and claims data for outpatient visits, hospitalizations,
and prescriptions. Disease diagnoses and comorbidities are coded
using the International Classiﬁcation of Diseases, Ninth Revision,
Clinical Modiﬁcation (ICD-9-CM) (http://www.cdc.gov/nchs/icd/
icd9cm.htm, n.d.); medications in pharmacy claims are identiﬁed
using the National Drug Code Directory (NDC) (http://www.fda.gov/
Drugs/InformationOnDrugs/ucm142438.htm, n.d.).
2.2. Sample selection
To be included in the sample, a patient had to be female, aged
55 years or older, and had to be prescribed at least one oral bisphospho-
nate including alendronate, risedronate or ibandronate anytime from
January 1, 2001 to December 31, 2010. Index drug was deﬁned as the
ﬁrst oral bisphosphonate prescribed for a patient as the ﬁrst oral osteo-
porosis treatment and the index date was deﬁned as the date of the ini-
tiation of the oral bisphosphonate from January 1, 2001 to December 31,
2010. A patient also had to be continuously enrolled in the health plan
for at least one year before (base year) and one year after index date
(follow-up year). Patients who had a diagnosis of Paget's disease of
bone (osteitis deformans; ICD-9-CM code 731.0) at any time in the da-
tabase were excluded from the study, as were patients with a diagnosis
of malignant neoplasm (ICD-9-CM codes, 140.xx to 208.xx, 230.xx to
239.xx, or 172.xx) anytime during the 2-year study period (Orsini
et al., 2005). Patients who took any oral osteoporosis therapy during
one year prior to index date were excluded.
2.3. Study variables
Compliance with osteoporosis treatment after initiation of an oral
bisphosphonate was the outcome of interest in this study. We deﬁned
compliance with therapy as a medication possession ratio (MPR) of
≥0.8 (Siris et al., 2009). The MPR was calculated as the number of
days' supply of all osteoporosis therapies received in the follow-up
year divided by 365 days (Peterson et al., 2007).
GI events were identiﬁed using ICD-9 diagnosis codes of dysphagia;
esophagitis; esophageal ulcer, stricture, perforation, and hemorrhage;
gastroesophageal reﬂux disease (GERD); gastric ulcer; duodenal ulcer;
peptic ulcer; acute gastritis; duodenitis; GI hemorrhage; and nausea
and vomiting (Appendix). The GI events during the follow-up period
could be recurrent or new. Osteoporotic fractures at baselinewere iden-
tiﬁed from primary and/or secondary diagnoses based on inpatient and
outpatient service claims during baseline year. Osteoporotic fractures
included hip, vertebral, and non-vertebral fractures, including those of
the pelvis, humerus, forearm, other femoral sites, tibia and ﬁbula, rib,
clavicle, scapula, and sternum. Fractures not considered as osteoporoticfractures were those of the hand, skull, digits, feet, and ankle and any
open fractures (Diez-Perez et al., 2012).
2.4. Statistical analyses
Descriptive statistics were used to summarize patient characteristics
at baseline.We compared characteristics of patientswhohad a recorded
GI event with those who had no GI event during the follow-up year,
using the χ2 test for binary and categorical variables and Wilcoxon
rank sum test for continuous variables.
Multivariate logistic regression was used to examine the association
between GI events and compliance (outcome variable) within the
follow-up year. The key independent variable in the model was the oc-
currence of GI events after initiation of an oral bisphosphonate during
the follow-up year (1 year). Covariates in the model included age at
the index date, presence of any osteoporotic fractures at baseline, occur-
rence of GI events at baseline, concomitant medication use at baseline
(gastroprotective agents, nonsteroidal anti-inﬂammatory drugs
[NSAIDs], corticosteroids, and estrogen), and comorbidities (inﬂamma-
tory bowel disease, celiac disease, diabetes, inﬂammatory joint disease,
depression, hypertension, urination problems, chronic kidney disease,
hyperparathyroidism, vitamin D deﬁciency, and fatigue). In addition to
the individual comorbidities,we included theDeyo-Charlson comorbid-
ity index (CCI) score, a measure that has been adapted for use with ad-
ministrative databases (Deyo et al., 1992) and is used to account for
comorbidities based on the presence of 19 predeﬁned comorbid condi-
tions, with higher CCI score denoting greater risk of death from comor-
bid disease (Charlson et al., 1987). Effects of the likelihood of
compliance on all independent variables were quantiﬁed and reported
in terms of odds ratios (ORs) with 95% conﬁdence intervals (CIs). For a
continuous independent variable (e.g., CCI), an OR b1.0 indicates a
lower likelihood of treatment compliance associated with the indepen-
dent variable. For a binary or categorical independent variable (e.g., age
group), anOR b1.0 indicates a lower likelihood of treatment compliance
in comparison with the reference group (i.e., 0 for a binary variable).
P-values were evaluated using Wald's tests and were considered
statistically signiﬁcant at a 5% level.
Furthermore, two sets of sensitivity analyses were conducted. One
set of sensitivity analyses assessed the regression-adjusted association
between GI event and compliance within the ﬁrst 3 and 6 months of
the follow-up year; the other set of sensitivity analyses examined the
association between GI events and compliance using MPR ≥0.6 as the
compliance threshold, a less stringent deﬁnition than in the main
analysis (MPR ≥0.8). All statistical analyses were conducted using SAS
software, version 9.3 (SAS Institute, Cary, NC).
3. Results
We identiﬁed 75,593womenwho received at least one oral bisphos-
phonate from 2001 to 2010 after meeting selection criteria (Fig. 1). Pa-
tient baseline characteristics and the rate of post-index GI events have
been previously reported (Modi et al., 2015). Brieﬂy, the mean (SD)
age of eligible women was 64.4 (8.4) years, 20,073 (26.6%) patients
experienced at least one baseline GI event and 4531 (6.0%) patients
had a recorded baseline osteoporotic fracture. A total of 21,142
(28.0%) patients experienced one or more GI events during the 1-
year follow-up. Patients who experienced a GI event during the base-
line year had a higher rate of GI events during the follow-up year
(51.2% vs. 19.6%) as compared with those who did not (data not
shown).
The distribution of patients by both compliance status (MPR ≥0.8 or
MPR ≥0.6) and the presence/absence of a GI event during follow-up is
shown in Table 1. The proportion of patients with MPR ≥0.8 was
lower among patients who experienced a GI event compared with pa-
tients who did not experience a GI event (34.1% vs 44.3%, P b 0.001).
The same pattern of lower compliance among patients with GI events
Fig. 1. Patient selection in the database.
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of patientswith GI events versus 58.0% of patientswith noGI events had
MPR ≥0.6 (P b 0.001) %). In addition, the mean MPR was signiﬁcantly
lower for patients with a GI event than for those with no GI eventTable 1
Compliance with oral bisphosphonate treatment among 75,593 female patients with and with
No GI event during follow-up year
N = 54,451 (72%)
MPR, mean (SD) 0.62 (0.34)
MPR ≥0.8, n (%) 24,102 (44.3)
MPR ≥0.6 31,605 (58.0)
a χ2 test for binary and categorical variables andWilcoxon rank sum test for continuous varia
gastrointestinal; MPR, medication possession ratio.(0.55 vs. 0.62, P b .001). Among all 75,593 patients initiating oral
bisphosphonates, irrespective of GI event status, a total of 31,306
(41.4%) patients (24,102 with no GI events and 7204 with GI events)
had MPR ≥0.8.out GI events during the follow-up year.
GI event during follow-up year





bles comparing patients with vs. without a GI event during the follow-up year.GI indicates
Table 2
Association between GI events and odds of compliance (MPR ≥0.8) with osteoporosis
therapy among osteoporotic women during the follow-up year adjusted for patient base-
line characteristics.
Effect Odds ratio (95% CI) P-value
GI event during follow-up year 0.71 (0.69–0.74) b.001
Age group (vs. 55–59 years) b.001
60–69 years 1.06 (1.03–1.10)
70–79 years 0.97 (0.93–1.02)
80–89 years 0.97 (0.92–1.03)
Osteoporotic fracture in baseline year 1.08 (1.05–1.11) b.001
GI event in baseline year 0.88 (0.85–0.92) b.001
Baseline medication use
Gastroprotective agent 1.04 (0.995–1.09) .087
NSAIDs 0.92 (0.89–0.96) b.001
Corticosteroids 0.88 (0.84–0.92) b.001
Estrogens 1.32 (1.27–1.37) b.001
CCI score (higher vs. lower) 0.95 (0.93–0.97) b.001
Comorbidity
Inﬂammatory bowel disease 1.01 (0.86–1.18) .89
Inﬂammatory joint disease 0.94 (0.91–0.98) .003
Celiac disease 1.09 (0.84–1.42) .51
Diabetes 0.85 (0.80–0.91) b.001
Depression 0.79 (0.74–0.84) b.001
Chronic kidney disease 1.07 (0.91–1.26) .42
Hypertension 0.89 (0.86–0.92) b.001
GI mucositis or urination problem 0.96 (0.91–1.02) .19
Hyperparathyroidism 1.02 (0.85–1.22) .84
Vitamin D deﬁciency 0.87 (0.74–1.02) .08
Fatigue 0.85 (0.82–0.89) b.001
CCI indicates Charlson comorbidity index; GI, gastrointestinal; MPR, medication posses-
sion ratio; NSAID, nonsteroidal anti-inﬂammatory drug.
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tion between GI events during follow and the likelihood ofMPR ≥0.8 are
shown in Table 2. Patients with at least one GI event within the follow-
up year were 29% less likely to be compliant with osteoporosis therapy
(odds ratio [OR], 0.71; 95% conﬁdence interval [CI], 0.69–0.74), as com-
pared with patients who did not experience any GI event within the
follow-up year. Other risk factors signiﬁcantly associated with lower
treatment compliance included the presence of GI events during base-
line, a higher baseline CCI score, therapy with NSAIDs or
corticosteroids during baseline and certain baseline conditions (inﬂam-
matory joint disease, diabetes, depression, hypertension, fatigue). Sig-
niﬁcantly better odds of compliance were evident for patients with
baseline osteoporotic fracture or who were prescribed estrogen during
baseline.
The results of a sensitivity analysis, in which data within the ﬁrst 3
months after initiation of oral bisphosphonates were analyzed, are
also consistent with those of the main analysis, showing that patients
with at least one GI event during the ﬁrst 3 months were 28% less likely
to be compliant with osteoporosis therapy (odds ratio [95% CI],
0.72 [0.69–0.76]), as compared to patients who did not experience
any GI event during the ﬁrst 3 months after initiation of oral
bisphosphonates (data not shown). The results of the sensitivity analy-
sis in which data within the ﬁrst 6 months after initiation of oral
bisphosphonates were analyzed suggest that patients with at least one
GI event during the ﬁrst 6 months were 29% less likely to be compliant
with osteoporosis therapy (odds ratio [95% CI], 0.71[0.68–0.74]), as
compared to patients who did not experience any GI event during the
ﬁrst 6 months after initiation of oral bisphosphonates (data not
shown). In addition, the sensitivity analysis in which compliance was
deﬁned as MPR ≥0.6 showed that patients experiencing at least one GI
event during the ﬁrst year after initiation of oral bisphosphonates
were 26% less likely to be compliant with osteoporosis therapy (odds
ratio [95% CI], 0.74[0.72–0.77]) as compared to patients who did
not have any GI event within one year after initiation of oral
bisphosphonates (data not shown). Results were consistent with the
results of the main analysis in which compliance was deﬁned as
MPR ≥0.8.4. Discussion
We found that 28% of women in this large observational study
experienced GI events during their ﬁrst year of osteoporosis therapy ini-
tiation with oral bisphosphonates and these women showed signiﬁ-
cantly lower likelihood of treatment compliance than women with no
GI events during their ﬁrst year of therapy. Other factors associated
with signiﬁcantly reduced likelihood of treatment compliance were a
GI event during the baseline year and use of concomitant NSAIDs or
corticosteroids at baseline. Overall, less than half (41%) of all women
included in this study were compliant with their osteoporosis therapy
during the follow-up year.
Our ﬁndings support the results of prior real-world studies investi-
gating compliance with bisphosphonates and the occurrence of GI
events. A similarly designed database study of 8822 new female users
of bisphosphonates in The Netherlands found that GI medications pre-
scribed for the ﬁrst time during the follow-up year (indicative of a GI
event) were independently associated with increased odds of non-
compliance with bisphosphonates (Penning-van Beest et al., 2008).
Likewise, in the Prospective Observational Scientiﬁc Study Investigating
Bone Loss Experience (POSSIBLE US), women reporting GI side
effects had signiﬁcantly greater odds of therapy discontinuation at 6
and 12months than those without GI side effects; moreover, GI side ef-
fects were more common among women prescribed bisphosphonates
than other agents (Woo et al., 2010).
No causal relationship between use of oral bisphosphonates and
occurrence of GI events after initiation of oral bisphosphonates
was established in this study. The occurrence of GI events after initiation
of oral bisphosphonates may be attributable to multiple factors includ-
ing oral bisphosphonate use, an underlying condition or concomitant
medication (e.g., NSAIDs, corticosteroids) that may cause or predispose
osteoporotic women to GI problems (Vestergaard et al., 2010).
The occurrence of GI events, regardless of whether the GI events were
caused by use of bisphosphonates or by use of other medications,
or concomitant medical conditions, was a risk factor for non-
compliance with osteoporosis therapy after initiation of oral
bisphosphonates.
In addition to GI events, certain baseline patient characteristics were
independently associated with more modest reductions in the likeli-
hood of compliance with osteoporosis therapy. These included older
age, greater comorbid burden, certain medical conditions and use of
speciﬁc medications. Previous studies have generally demonstrated
greater compliance in older patients although the odds of improved
compliance tended to diminish at age 65 and above (Penning-van
Beest et al., 2008; Curtis et al., 2009; McCombs et al., 2004). Age may
also be a proxy for higher comorbid burden and use of multiple medica-
tions. Our results showed a consistent negative association amongother
factors that may be linked with older age such as higher comorbidity
score and NSAID use which compliments previous ﬁndings (Curtis
et al., 2009;McCombs et al., 2004) althoughNSAID use has also been as-
sociated with higher odds of compliance (Penning-van Beest et al.,
2008). Diabetes and glucocorticoid use have been linked with reduced
compliance and persistence which is consistent with our results
(Curtis et al., 2009; McCombs et al., 2004; Netelenbos et al., 2011). We
also observed lower odds of compliance among patients with comorbid
inﬂammatory joint disease, hypertension, depression or fatigue, which
may be surrogates for higher overall disease burden. However, other
factors that are unobservable in claims databases, such as patient beliefs
regarding safety and efﬁcacy, are also barriers to compliance with oral
bisphosphonates (McHorney et al., 2007). The conﬂicting results in
the literature are likely attributable in part to differences in study
methodology but also suggest that the causes of poor compliance are
multifactorial.
The results of this study indicate that less than half of women in a
managed care population with osteoporosis comply with osteoporosis
therapy during their ﬁrst year after being prescribed an oral
9E.S. Siris et al. / Bone Reports 4 (2016) 5–10bisphosphonate. In prior studies, factors associated with poor compli-
ance included patients' failure to perceive increased risk of fracture,
lack of satisfaction with treatment, a daily treatment regimen, and con-
cern about side effects (Penning-van Beest et al., 2008; Barrett-Connor
et al., 2012; Solomon et al., 2011; Siris et al., 2011; Sale et al., 2011).
Our study results are similar to those of prior studies of medical condi-
tions requiring chronic long-term therapy, forwhich suboptimal patient
compliance with medications is a common problem, particularly with
regard to conditions that are asymptomatic, such as osteoporosis before
fracture and hypercholesterolemia before a cardiovascular event. A re-
cent study estimated adherence to statin therapy among new statin
users (whichwas calculated by dividing the total number of tablets dis-
pensed during the 1 year follow-up after initiation of statin by the total
number of days in the observation period) reported that the proportion
of non-compliant patients ranged from 38.3% to 50.0% during the 1 year
follow-up period (Lemstra and Blackburn, 2012). Similarly, Zhang et al.
(Zhang et al., 2011) in their retrospective cohort study of 52,414 pa-
tients with type 2 diabetes, reported that only 52% of patients had a 2-
year MPR N0.8 for statin therapy.
Ascertaining the factors associated with poor compliance with
bisphosphonate therapy can help clinicians to identify and mitigate
risk factors for patients who require closer monitoring and encourage-
ment about the need for therapy. Better compliance with osteoporosis
therapies is associated with greater reduction in fracture risk (Cotte
et al., 2008; Patrick et al., 2010; Siris et al., 2006) and reduced mortality
risk in women receiving osteoporosis therapy (Center et al., 2011).
Moreover, economic modeling suggests that non-compliance is costly
from the payer's and patients' perspective including direct health-care
costs paid by health plans and individual patient's out-of-pocket contri-
bution (Cotte and De Pouvourville, 2011; Hiligsmann et al., 2010). Im-
proving compliance with osteoporosis therapy could reduce the
incremental burden with respect to healthcare resource utilization
and costs for health plans. Patient education about osteoporosis and
fracture risk should be provided for patients prescribed osteoporosis
therapy, particularly for those at risk of poor compliance, such as
women with GI events at baseline. Moreover, the results of this study
suggest that particular attention should be paid to patients who experi-
ence GI events during therapy, as well as those receiving concomitant
NSAIDs or corticosteroids, who may be more likely to experience GI
events.
4.1. Limitations
This analysis used administrative claims data on medication pre-
scriptions and estimated MPR based on pharmacy claims and medi-
cal claims. We cannot be certain that dispensed medications were
actually taken as prescribed; this drawback could result in overesti-
mation of compliance. Moreover, information to fully characterize
patients with regard to risk of a GI event or osteoporotic fracture
(for example, bone mineral density and vitamin D levels) was not
available from the database. There may also have been other unob-
served patient characteristics that were not accounted for in the
logistic regression model examining the association between GI
events and compliance. For example, we excluded patients with
evidence of use of any oral osteoporosis therapy any time prior to
the index date during the study period in which patients were con-
tinuously enrolled in health plans in order to focus on patients
with no prior exposure to oral bisphosphonate treatment. However,
it is possible that some patients may have been treated with oral
bisphosphonates before enrolling in the health plan or before the
study period and prior experience with therapy may have inﬂuenced
their degree of compliance during the follow-up period. However,
we would expect that this potential inﬂuence would be limited to a
small number of patients because previous research suggests that
the large majority of patients who discontinue therapy and then
re-initiate therapy do so within 1 year (Balasubramanian et al.,2013). Lastly, no temporal relationships between occurrence of GI
events and discontinuation of bisphosphonates were considered in
this analysis since only association was examined.
4.2. Conclusions
The results of this study indicate that less than half of women com-
ply with osteoporosis therapy during their ﬁrst year after being pre-
scribed an oral bisphosphonate, and women who experience GI events
have signiﬁcantly lower odds of compliance. Further studies are needed
to evaluate the burden of GI events on healthcare resource use and
costs.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bonr.2015.10.006.
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